Nervgen Pharma Corp Stock Earnings Per Share
| NGENF Stock | USD 1.86 0.01 0.54% |
NervGen Pharma Corp fundamentals help investors to digest information that contributes to NervGen Pharma's financial success or failures. It also enables traders to predict the movement of NervGen OTC Stock. The fundamental analysis module provides a way to measure NervGen Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to NervGen Pharma otc stock.
NervGen |
NervGen Pharma Corp OTC Stock Earnings Per Share Analysis
NervGen Pharma's Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Current NervGen Pharma Earnings Per Share | (0.28) X |
Most of NervGen Pharma's fundamental indicators, such as Earnings Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, NervGen Pharma Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
| Competition |
According to the company disclosure, NervGen Pharma Corp has an Earnings Per Share of -0.283 times. This is 103.38% lower than that of the Healthcare sector and 94.09% lower than that of the Biotechnology industry. The earnings per share for all United States stocks is 109.07% higher than that of the company.
NervGen Earnings Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NervGen Pharma's direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of NervGen Pharma could also be used in its relative valuation, which is a method of valuing NervGen Pharma by comparing valuation metrics of similar companies.NervGen Pharma is currently under evaluation in earnings per share category among its peers.
NervGen Fundamentals
| Return On Equity | -1.42 | |||
| Return On Asset | -0.67 | |||
| Current Valuation | 48.78 M | |||
| Shares Outstanding | 58.68 M | |||
| Shares Owned By Insiders | 25.27 % | |||
| Price To Book | 5.13 X | |||
| EBITDA | (11.33 M) | |||
| Net Income | (12.73 M) | |||
| Cash And Equivalents | 11.65 M | |||
| Cash Per Share | 0.20 X | |||
| Total Debt | 324.69 K | |||
| Debt To Equity | 0.03 % | |||
| Current Ratio | 4.25 X | |||
| Book Value Per Share | 0.31 X | |||
| Cash Flow From Operations | (8.27 M) | |||
| Earnings Per Share | (0.28) X | |||
| Beta | 1.7 | |||
| Market Capitalization | 87.43 M | |||
| Total Asset | 17.9 M | |||
| Net Asset | 17.9 M |
About NervGen Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NervGen Pharma Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NervGen Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NervGen Pharma Corp based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in NervGen OTC Stock
NervGen Pharma financial ratios help investors to determine whether NervGen OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in NervGen with respect to the benefits of owning NervGen Pharma security.